Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies

Clinical Transplantation
Timothy MathewPeter Friend

Abstract

We examined the rates of malignancy at 2 yr after transplantation in renal allograft patients receiving sirolimus (SRL) in continuous combination with cyclosporine (CsA), SRL as base therapy or SRL maintenance therapy after early withdrawal of CsA. A total of 1295 patients were enrolled in two double-blind studies comparing SRL with azathioprine (AZA) or placebo administered in continuous regimens with CsA. In two other trials (n = 161), SRL given as base therapy was compared with CsA. In the fifth trial, patients were randomly assigned at 3 months to either remain on CsA + SRL therapy (n = 215) or to have CsA eliminated with SRL being continued in concentration-controlled doses (n = 215). At 2 yr after transplantation, patients receiving SRL in continuous combination with CsA had a significantly lower incidence of skin cancer compared with patients receiving placebo. Patients receiving SRL as base therapy had no malignancies compared with a 5% incidence in those receiving CsA. The incidence of malignancy was significantly lower in patients receiving concentration-controlled SRL with elimination of CsA compared with those who remained on CsA + SRL. Based on the currently available data, patients receiving SRL-based therapy with...Continue Reading

References

Jan 1, 1994·Medicinal Research Reviews·S N SehgalB M Weichman
Feb 1, 1997·Transplantation Proceedings·M BehrendR Pichlmayr
Jul 27, 1999·Skin Pharmacology and Applied Skin Physiology·J W FluhrE Berardesca
Jan 22, 2000·Journal of the American Academy of Dermatology·P JensenS Hansen
Jun 4, 2002·Transplantation·Fu L LuanManikkam Suthanthiran

❮ Previous
Next ❯

Citations

Mar 28, 2007·Pathology Oncology Research : POR·Gyula VégsoJeno Járay
Aug 21, 2007·Molecular Diagnosis & Therapy·Mercè BrunetOlga Millán
Feb 11, 2010·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·G Hofbauer
Mar 8, 2011·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·David GonzálezFernando Santos
Nov 8, 2008·International Urology and Nephrology·Ramesh SaxenaXin J Zhou
Feb 20, 2009·Current Treatment Options in Oncology·M J Patel, N J Liégeois
Jun 1, 2012·Current Treatment Options in Cardiovascular Medicine·Michelle M Kittleson
Jul 27, 2012·The New England Journal of Medicine·Sylvie EuvrardUNKNOWN TUMORAPA Study Group
May 28, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Jeffrey S ZaltzmanSerge Jothy
Nov 4, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Sophie DomhanAmir Abdollahi
Dec 12, 2012·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Robert P CarrollPaul N Harden
Oct 8, 2005·Transplantation·Barry D KahanCharles T Van Buren
Nov 16, 2005·Transplantation·Joachim AndrassyMarkus Guba
Aug 19, 2007·Transplantation·Gabriel M DanovitchSuphamai Bunnapradist
Feb 8, 2011·American Journal of Clinical Oncology·James Leroy Wells, Keisuke Shirai
Dec 20, 2007·Current Opinion in Nephrology and Hypertension·Brahm Vasudev, Sundaram Hariharan
May 18, 2010·Current Opinion in Hematology·Courtney D DiNardo, Donald E Tsai
Dec 9, 2008·Current Opinion in Organ Transplantation·Sheri M Krams, Olivia M Martinez
Dec 16, 2005·Nephrology·Vincent Ws Lee, Jeremy R Chapman
Jan 10, 2006·Seminars in Dialysis·Martin S Zand
Jun 22, 2006·International Journal of Clinical Practice·N KolheJ Pattison
Jan 30, 2008·BMC Dermatology·Aubrey RauktysSandra L Dabora
Mar 6, 2007·Drugs·Joshua J AugustineDonald E Hricik
Jun 24, 2008·Drugs·Anil Kapoor
May 31, 2014·World Journal of Gastroenterology : WJG·Rajeev Desai, James Neuberger
May 22, 2013·Clinical & Developmental Immunology·J MorscioT Tousseyn
Mar 19, 2014·Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation·Jeremy R Chapman, Stephen V Lynch
Sep 18, 2010·Mediators of Inflammation·Aswin HariP Régine Mydlarski
Dec 21, 2007·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·Jerry D BrewerAmy L Weaver
Jul 13, 2014·American Journal of Clinical Dermatology·Lauren BrinJerry D Brewer
May 9, 2014·Journal of Nephrology·Gianluigi ZazaAntonio Lupo
Dec 17, 2014·Transplantation Reviews·Anjana A Pillai
Jul 27, 2014·Actas dermo-sifiliográficas·J Bernat-GarcíaJ Crespo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.